Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

Dang, C N; Katakam, L I; Smith, P B; Cotten, C M; Goldberg, R N; Chandler, N; Thornburg, C D; Bidegain, M

Dang, C N; Katakam, L I; Smith, P B; Cotten, C M; Goldberg, R N; Chandler, N; Thornburg, C D; Bidegain, M.

Affiliation

Dang CN; Department of Pharmacy, Duke University Medical Center, Durham, NC 27710, USA.

J Perinatol ; 31(3): 188-92, 2011 Mar.

Article in En | MEDLINE | ID: mdl-20671714

Subject(s)

Blood Transfusion; Factor VIIa/administration & dosage; Hemorrhage/drug therapy; Female; Gestational Age; Humans; Infant, Newborn; Male; Recombinant Proteins/administration & dosage; Recurrence; Retrospective Studies; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Transfusion / Factor VIIa / Hemorrhage Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Newborn Language: En Journal: J Perinatol Journal subject: PERINATOLOGIA Year: 2011 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google